Blair Rainer sold $12.7M of DHR (indirect holdings)

Blair Rainer (President & CEO) sold 58,255 indirectly-held shares of DANAHER CORP /DE/ (DHR) at an average of $218.63 ($217.77–$219.35, $12.74M total) across 3 trades on 2026-08-21.

Original reporting
SEC EDGAR · Blair Rainer
Published Aug 24, 2026, 9:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 24, 2026, 9:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$DHR
Bearish
medium confidence
Mentioned
$DHR
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$DHRBearishLow
01

Why it matters

The sale reduces insider ownership to zero, potentially affecting investor perception of confidence.

02

Market read

Direct impact on DHR stock; limited broader market effect.

03

What to watch

No 10b5‑1 plan; sale may be tax‑driven or personal liquidity need.

Relevance 7/10Novelty 7/10Timing: filing released on 2026-08-24

Background

Form 4 filings disclose insider transactions; large executive sales are closely watched.

Company-level read

Ticker impact

$DHRBearishMedium confidence
Context

President & CEO Blair Rainer sold 58,255 shares for $12.7M, reducing his stake to zero.

Expected impact

Potential short-term dip of 1-2% as market digests the sale.

Evidence & confidence

Sale size is material for a large-cap; insider is top executive, but no pre‑arranged plan disclosed.

Market effects

May prompt scrutiny of Danaher governance but limited sector impact.

U.S. market focus; no broader regional effect.

Minimal global relevance beyond Danaher investors.

Counterpoint

Insider sell could be routine diversification, not a negative signal.

Key entities

  • Blair Rainer

    President & CEO of Danaher Corp.

  • Danaher Corp.

    Global science and technology conglomerate.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$DHRMed

Beckman Coulter receives FDA clearance for bacterial infection test

Beckman Coulter Diagnostics, part of Danaher Corporation, received FDA clearance for the Access MeMed BV assay, a blood test distinguishing bacterial from viral infections in patients aged 90 days and older. The test runs on the company's DxI 9000 and Access 2 immunoassay analyzers, providing results in 15 minutes. Developed with MeMed, the test measures immune-response proteins to generate a bacterial infection likelihood score.

$DHRMed

UBS reiterates Danaher stock Buy rating on Q3 results and outlook

UBS reiterated a Buy rating on Danaher (DHR) with a $260 price target, citing Q3 results and outlook. The stock, near its 52-week high, has risen 27.6% in six months. Danaher reported Q3 core revenue growth of 2.5% to 3.0% and adjusted earnings of $2.11 per share, exceeding expectations. Stifel also raised its price target to $260, noting strong nonrespiratory growth.